Trial · NCT04943159
Afamelanotide in Patients Suffering With Acne Vulgaris
NCT04943159, Phase 2, Completed, Clinuvel Pharmaceuticals Limited; results first posted 2021-10-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Afamelanotide in Patients Suffering With Acne Vulgaris. Trials, record NCT04943159. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04943159
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Afamelanotide in Patients Suffering With Acne Vulgaris
- NCT number
- NCT04943159
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Clinuvel Pharmaceuticals Limited
- Conditions
- Acne Vulgaris
- Interventions
- Afamelanotide
- First posted
- 2021-06-29
- Last updated
- 2021-10-26
- Results first posted
- 2021-10-26
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Change in Number of Facial Inflammatory Acne-related Lesions. | From baseline to Day 56. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Change in Number of Facial Inflammatory Acne-related Lesions. | From baseline to Day 56. | A pooled analysis of all the patients treated by afamelanotide (group A and group B) was conducted as only 3 patients were recruited in the study (2 in group A and one in group B) due to difficulties in recruitment. | Lesions | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Change in Number of Facial Inflammatory Acne-related Lesions. | Afamelanotide (Pooled Analysis) | Baseline | 46 | Standard Error 30.3 | Lesions |
| The Change in Number of Facial Inflammatory Acne-related Lesions. | Afamelanotide (Pooled Analysis) | Day 56 | 23.7 | Standard Error 15.6 | Lesions |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Afamelanotide (Pooled Analysis) | 3 | |
| Overall Study | COMPLETED | Afamelanotide (Pooled Analysis) | 3 | |
| Overall Study | NOT COMPLETED | Afamelanotide (Pooled Analysis) | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Afamelanotide (Pooled Analysis) | 1 | 3 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Afamelanotide (Pooled Analysis) | ||
| Total, other adverse events | Afamelanotide (Pooled Analysis) | 1 | 3 |
| Total, serious adverse events | Afamelanotide (Pooled Analysis) | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04943159
GET https://conductscience.org/api/trials/v1/NCT04943159/registered